Fuse Group issues 100M shares for E-Mo Biotech; Xie becomes 31.97% owner

FUSE GROUP HOLDING INC.

Fuse Group acquired all of E-Mo Biotech in exchange for 100 million common shares.
E-Mo Biotech is a development-stage vaccine/immunology/diagnostics firm with no commercial sales.
Qiyi Xie receives 57.25M shares (31.97% of Fuse Group) and becomes largest shareholder, replacing Landbond Home.
Shares issued to Xie under Reg D; to other sellers under Reg S; no underwriter used.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.